8-K: Viking Therapeutics Advances Obesity Pipeline, Reports Q3 Loss

Viking Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its obesity drug pipeline with VK2735 subcutaneous and oral formulations, despite increased net losses.

Summary

• Viking Therapeutics announced its financial results for the third quarter and nine months ended September 30, 2025, alongside a corporate update.
• The Phase 3 VANQUISH trials for subcutaneous VK2735 in obesity are proceeding on schedule, with enrollment in VANQUISH-1 expected to complete by the end of 2025 and VANQUISH-2 in Q1 2026.
• The Phase 2 VENTURE-Oral Dosing study of VK2735 successfully achieved its primary and secondary endpoints, demonstrating statistically significant reductions in body weight of up to 12.2% from baseline after 13 weeks.
• The oral tablet formulation of VK2735 showed encouraging safety and tolerability, with 98% of reported drug-related adverse events categorized as mild or moderate.
• An exploratory maintenance dosing cohort in the oral study demonstrated that rapid weight loss was maintained and further extended following down-titration to a lower daily dose.
• A Phase 1 maintenance dosing study for VK2735, exploring various oral and subcutaneous regimens for long-term weight loss maintenance, is underway with results expected mid-2026.
• The dual amylin and calcitonin receptor agonist (DACRA) program is advancing, with an Investigational New Drug (IND) application planned for Q1 2026.
• The company ended the third quarter of 2025 with a strong cash, cash equivalents, and short-term investments position of $715 million.
• Net loss for the third quarter ended September 30, 2025, was $90.8 million, or $0.81 per share, compared to a net loss of $24.9 million, or $0.22 per share, for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $202.0 million, or $1.80 per share, compared to $74.5 million, or $0.69 per share, for the corresponding period in 2024.
• Research and development expenses increased to $90.0 million in Q3 2025 from $22.8 million in Q3 2024, primarily due to increased clinical study and manufacturing costs.

Sentiment

Score: 8

Explanation: The filing demonstrates exceptional progress in Viking's lead obesity program, VK2735, with positive efficacy and safety data for both subcutaneous and oral formulations, and rapid advancement into Phase 3. The initiation of a maintenance dosing study and the amylin agonist program further strengthen the pipeline. While financial losses increased due to R&D, the company maintains a strong cash position, which management states is sufficient for current development plans. This indicates robust operational execution and promising therapeutic potential.

Positives

• Phase 3 VANQUISH trials for subcutaneous VK2735 in obesity are proceeding on schedule with rapid enrollment, reflecting enthusiasm from patients and investigators.
• The Phase 2 VENTURE-Oral Dosing study of VK2735 successfully met primary and secondary endpoints, demonstrating statistically significant mean weight loss of up to 12.2% (26.6 lbs.) after 13 weeks.
• Oral VK2735 exhibited promising safety and tolerability, with 98% of drug-related treatment emergent adverse events (TEAEs) reported as mild or moderate.
• An exploratory maintenance dosing cohort for oral VK2735 showed that rapid weight loss was maintained and further extended with lower daily doses, supporting a potential maintenance strategy.
• A Phase 1 maintenance dosing study for VK2735 (oral/subcutaneous) has been initiated to explore flexible long-term weight loss maintenance regimens.
• The dual amylin and calcitonin receptor agonist (DACRA) program is advancing, with an IND filing planned for Q1 2026.
• The company maintains a strong quarter-end cash position of $715 million, providing sufficient resources to fund VK2735 Phase 3 clinical trials and other pipeline development.

Negatives

• Net loss for the third quarter ended September 30, 2025, increased to $90.8 million ($0.81 per share) from $24.9 million ($0.22 per share) in Q3 2024.
• Net loss for the nine months ended September 30, 2025, increased to $202.0 million ($1.80 per share) from $74.5 million ($0.69 per share) in the corresponding period of 2024.
• Research and development expenses significantly increased to $90.0 million in Q3 2025 from $22.8 million in Q3 2024, primarily driven by clinical studies and manufacturing.
• Cash, cash equivalents, and short-term investments decreased to $715 million at September 30, 2025, from $903 million at December 31, 2024.

Risks

• Risks associated with the success, cost, and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and other incretin and receptor agonists.
• Risks that prior clinical and preclinical results may not be replicated in future studies.
• Risks regarding regulatory requirements and the ability to obtain necessary approvals for product candidates.
• Other risks described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Viking expects to complete enrollment in the VANQUISH-1 study by the end of 2025 and VANQUISH-2 in Q1 2026. The company plans to meet with regulatory authorities in Q4 2025 to discuss next steps for oral VK2735. An Investigational New Drug (IND) application for the amylin agonist program is planned for Q1 2026. Results from the Phase 1 maintenance dosing study of VK2735 are anticipated in mid-2026.

Management Comments

• "During the first three quarters of 2025, Viking made strong and steady progress with each of our active programs, with new data reported in the third quarter that further positions our lead obesity program as potentially best-in-class." Brian Lian, Ph.D., CEO.
• "The impressive oral efficacy and low-dose maintenance data highlight VK2735s differentiated profile, offering additional dosing options to complement weekly subcutaneous dosing." Brian Lian, Ph.D., CEO.
• "The rapid pace of enrollment in these trials reflects the enthusiasm weve received from both patients and clinical investigators." Brian Lian, Ph.D., CEO.
• "Importantly, our balance sheet remains strong, providing sufficient resources to enable the development of VK2735 through the VANQUISH Phase 3 clinical trials, and to continue development of additional clinical programs in our pipeline." Brian Lian, Ph.D., CEO.

Industry Context

The filing highlights the significant role of GLP-1 and GIP receptors in metabolic control, positioning VK2735 as a dual agonist in the highly competitive and rapidly growing obesity treatment market. The development of both subcutaneous and oral formulations, along with maintenance dosing strategies, addresses diverse patient preferences and long-term adherence, which are critical factors in this therapeutic area. The advancement of an amylin agonist program suggests a strategy to develop combination therapies or alternative options for patients not suitable for GLP-1 treatments, reflecting a broader industry trend towards multi-modal approaches to obesity and metabolic disorders.

Comparison to Industry Standards

• VK2735 is positioned as a "potentially best-in-class" dual GLP-1/GIP receptor agonist, a class that includes highly successful drugs like tirzepatide (Zepbound/Mounjaro).
• The oral formulation of VK2735 demonstrated up to 12.2% mean weight loss after 13 weeks, which is competitive with other oral GLP-1 agonists in early to mid-stage development.
• The subcutaneous formulation of VK2735 showed up to 14.7% mean body weight reduction after 13 weekly doses in Phase 2, indicating strong efficacy comparable to leading injectable GLP-1/GIP agonists.
• The company's strategy to offer both oral and subcutaneous formulations of the same molecule aims to mitigate potential safety or tolerability challenges during patient transitions, a differentiating factor in the market.
• The development of amylin agonists for combination therapy or alternative options aligns with industry efforts to enhance efficacy and expand treatment options beyond current GLP-1/GIP monotherapies.

Stakeholder Impact

• Shareholders: Positive impact from strong clinical progress and potential "best-in-class" drug candidates, which could drive future value. Increased R&D spend and net losses are a short-term negative but are investments in long-term growth.
• Patients with Obesity/Metabolic Disorders: Potential for new, effective, and flexible treatment options (subcutaneous, oral, maintenance dosing) for weight loss and metabolic control.
• Employees: Continued employment and potential growth opportunities due to advancing pipeline and clinical development.
• Regulatory Authorities: Ongoing engagement with FDA for Phase 3 and future oral VK2735 development.

Next Steps

• Complete enrollment in the VANQUISH-1 study by the end of 2025.
• Complete enrollment in the VANQUISH-2 study in Q1 2026.
• Meet with regulatory authorities in Q4 2025 to discuss next steps for oral VK2735.
• File an Investigational New Drug (IND) application for the amylin agonist program in Q1 2026.
• Report results from the Phase 1 maintenance dosing study of VK2735 in mid-2026.
• Present additional Phase 2a VENTURE study data at ObesityWeek in November.
• Participate in several investor conferences in November 2025 and January 2026.

Key Dates

Recommendation

The filing demonstrates exceptional progress in Viking's lead obesity program, VK2735, with both subcutaneous and oral formulations showing strong efficacy and favorable safety profiles. The rapid advancement into Phase 3 for the subcutaneous version and the successful Phase 2 oral data, coupled with a clear path for regulatory discussions and further development, position VK2735 as a potentially significant player in the lucrative obesity market. While the company reported increased net losses, this is a direct result of substantial, necessary investment in R&D to accelerate these promising clinical programs. The strong cash position provides ample runway for these critical trials. The strategic development of multiple formulations and a new amylin agonist program further de-risks and diversifies the pipeline. This robust clinical execution and strategic foresight warrant a "strong buy" recommendation for long-term investors.

Keywords

Viking Therapeutics, VKTX, obesity, GLP-1, GIP, VK2735, weight loss, metabolic disorders, biopharmaceutical, clinical trials, Phase 3, oral formulation, subcutaneous, amylin agonist, DACRA, financial results, R&D, cash position